Corcept Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Corcept Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
0.4%
Buyback Yield
Total Shareholder Yield | 0.4% |
Future Dividend Yield | 0% |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 25% Price Jump
Dec 04Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
Sep 28If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity
Sep 06Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)
Aug 01With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For
Apr 15We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit
Feb 22Corcept Therapeutics: Key Catalysts Ahead
Feb 19After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar
Dec 23Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if CORT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CORT's dividend payments have been increasing.
Dividend Yield vs Market
Corcept Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (CORT) | n/a |
Market Bottom 25% (US) | 1.4% |
Market Top 25% (US) | 4.5% |
Industry Average (Pharmaceuticals) | 2.5% |
Analyst forecast (CORT) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate CORT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CORT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate CORT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CORT has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 08:32 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Corcept Therapeutics Incorporated is covered by 23 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Tazeen Ahmad | BofA Global Research |
David Buck | B. Riley Securities, Inc. |
Edward Nash | Canaccord Genuity |